Edgewise Income Quality from 2010 to 2024

EWTX Stock  USD 32.20  0.22  0.69%   
Edgewise Therapeutics Income Quality yearly trend continues to be fairly stable with very little volatility. Income Quality is likely to outpace its year average in 2024. Income Quality is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. View All Fundamentals
 
Income Quality  
First Reported
2010-12-31
Previous Quarter
0.91798369
Current Value
0.95
Quarterly Volatility
0.05982307
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 14.9 M or Depreciation And Amortization of 1.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.3. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Income Quality Growth Pattern

Below is the plot of the Income Quality of Edgewise Therapeutics over the last few years. It is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. Edgewise Therapeutics' Income Quality historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Quality10 Years Trend
Slightly volatile
   Income Quality   
       Timeline  

Edgewise Income Quality Regression Statistics

Arithmetic Mean0.92
Geometric Mean0.91
Coefficient Of Variation6.53
Mean Deviation0.04
Median0.94
Standard Deviation0.06
Sample Variance0
Range0.1718
R-Value(0.50)
Mean Square Error0
R-Squared0.25
Significance0.06
Slope(0.01)
Total Sum of Squares0.05

Edgewise Income Quality History

2024 0.95
2023 0.92
2021 0.78
2020 0.85

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Income Quality, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Quality 0.92  0.95 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.